Glucagon-Like Peptide-1 Receptor Agonist Protects Against Diabetic Cardiomyopathy by Modulating microRNA-29b-3p/SLMAP
Ping Fang,Zhengqin Ye,Ran Li,Dunmin She,Guannan Zong,Liya Zhang,Ying Xue,Keqin Zhang
DOI: https://doi.org/10.2147/DDDT.S400249
2023-03-12
Abstract:Ping Fang, 1 Zhengqin Ye, 1 Ran Li, 1 Dunmin She, 2 Guannan Zong, 1 Liya Zhang, 1 Ying Xue, 1 Keqin Zhang 1 1 Department of Endocrinology and Metabolism, Tongji Hospital, School of Medicine, Tongji University, Shanghai, 200065, People's Republic of China; 2 Department of Endocrinology, Northern Jiangsu People's Hospital Affiliated to Yangzhou University, Yangzhou, Jiangsu, 225001, People's Republic of China Correspondence: Ying Xue; Keqin Zhang, Department of Endocrinology and Metabolism, Tongji Hospital, School of Medicine, Tongji University, No. 389, Xincun Road, Shanghai, 200065, People's Republic of China, Tel +86-21-66111061, Email ; Purpose: Our aims were to investigate the pathogenesis of diabetic cardiomyopathy (DCM) and to explore the protective effect of glucagon-like peptide-1 receptor agonist (GLP-1RA) on DCM. Methods: After 12 weeks of treatment with exenatide-loaded microspheres, a long-acting GLP-1RA, in DCM mice, cardiac structure and function were evaluated by plasma B-type natriuretic peptide (BNP), echocardiography, H&E, oil red and Sirius staining. The expression of glucagon-like peptide-1 receptor in mouse heart tissue was determined by immunofluorescence staining. The label-free proteomic analysis of cardiac proteins was conducted among control, DCM and DM+GLP-1RA groups. Then, quantitative real-time PCR, Western blotting and dual-luciferase reporter assay were performed to verify the regulation of target protein by the upstream microRNA (miRNA). Results: GLP-1RA treatment obviously improved serum BNP, myocardial fibrosis, lipid deposition of the myocardium and echocardiography parameters in DCM mice. Sarcolemmal membrane-associated protein (SLMAP) was one of 61 differentially expressed cardiac proteins found in three groups by proteomic analysis. Up-regulation of microRNA-29b-3p (miR-29b-3p) and down-regulation of SLMAP were found in the ventricular myocardium of GLP-1RA-treated DCM mice. SLMAP was a target of miR-29b-3p, while GLP-1RA regulated SLMAP expression through miR-29b-3p. Furthermore, inhibition of glucagon-like peptide-1 receptor (GLP-1R) in cardiomyocytes reversed the effects of GLP-1RA on miR-29b/SLMAP. Conclusion: SLMAP may play roles in the pathogenesis of DCM and may be a target of GLP-1RA in protecting against DCM. After binding to myocardial GLP-1R, GLP-1RA can regulate the expression of myocardial SLMAP through miR-29b-3p. Keywords: diabetic cardiomyopathy, microRNA-29b-3p, proteomics, sarcolemmal membrane-associated protein, glucagon-like peptide-1 receptor agonist It is well known that diabetes mellitus and cardiovascular disease are closely related. The prevalence and mortality of cardiovascular disease in diabetic patients are 2–4 times higher than those in non-diabetic individuals. 1,2 The mortality of cardiovascular disease accounts for 65% of diabetes-related deaths. 3 In several population-based studies, diabetes mellitus was associated with an increased risk of heart failure after adjusting for other risk factors such as obesity, dyslipidemia, hypertension, and coronary artery disease. 4 Diabetic cardiomyopathy (DCM), a type of cardiovascular damage which increases the risk of heart failure in diabetic patients, is defined as the changes in cardiac structure and function induced by DM in the absence of coronary artery disease, ischemic heart disease, valvular heart disease, hypertension or other cardiac pathologies. It is characterized by structural changes, including myocardial hypertrophy, myocardial lipotoxicity and interstitial fibrosis, and functional changes such as diastolic and systolic dysfunction. 5 Multifactorial mechanisms such as glucotoxicity, 6 lipotoxicity, 7 inflammation, 8 mitochondrial dysfunction 9,10 oxidative stress 11 and deranged calcium homeostasis 12 are believed to be involved in the development of DCM. Despite various progress has been made, the exact pathogenesis of DCM still needs to be clearly elucidated, and specific treatment strategies for DCM remain to be explored. Glucagon-like peptide-1 receptor agonist (GLP-1RA) is an effective drug for the treatment of type 2 diabetes and obesity. A meta-analysis of seven clinical trials 13–19 using GLP-1RA have indicated that GLP-1RA treatment can reduce the major adverse cardiac events of type 2 diabetic patients by 12%, and decrease the hospitalization rate of heart failure by 9%. 20 Previous studies have indicated that sarcolemmal membrane associated protein (SLMAP) may be associated with heart failure 21 and microvascular disease associated with type 2 diabetes.<su -Abstract Truncated-
pharmacology & pharmacy,chemistry, medicinal